莎普爱思：股东陈德康拟减持公司不超2%股份

Group 1 - The major shareholder Chen Dekang, holding 11.67% of the shares, plans to reduce his stake by up to 7.5185 million shares, which is no more than 2% of the company's total share capital, within three months after 15 trading days from the announcement date [1] - The company's wholly-owned subsidiary, Zhejiang Shapu Health Management Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of a new drug, hydrochloride pilocarpine eye drops, which is intended for the treatment of presbyopia in adults [1]